66 research outputs found
Recommended from our members
Annular Mode Time Scales in the Intergovernmental Panel on Climate Change Fourth Assessment Report Models
The ability of climate models in the Intergovernmental Panel on Climate Change Fourth Assessment Report to capture the temporal structure of the annular modes is evaluated. The vertical structure and annual cycle of the variability is quantified by the e-folding time scale of the annular mode autocorrelation function. Models vaguely capture the qualitative features of the Northern and Southern Annular Modes: Northern Hemisphere time scales are shorter than those of the Southern Hemisphere and peak in boreal winter, while Southern Hemisphere time scales peak in austral spring and summer. Models, however, systematically overestimate the time scales, particularly in the Southern Hemisphere summer, where the multimodel ensemble average is twice that of reanalyses. Fluctuation-dissipation theory suggests that long time scales in models could be associated with increased sensitivity to anthropogenic forcing. Comparison of model pairs with similar forcings but different annular mode time scales provides a hint of a fluctuation-dissipation relationship
Recommended from our members
Potential of 18F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer
Purpose We investigated the metabolic response of lung cancer to radiotherapy or chemoradiotherapy by 18F-FDG PET and its utility in guiding timely supplementary therapy. Methods: Glucose metabolic rate (MRglc) was measured in primary lung cancers during the 3 weeks before, and 10–12 days (S2), 3 months (S3), 6 months (S4), and 12 months (S5) after radiotherapy or chemoradiotherapy. The association between the lowest residual MRglc representing the maximum metabolic response (MRglc-MMR) and tumor control probability (TCP) at 12 months was modeled using logistic regression. Results: We accrued 106 patients, of whom 61 completed the serial 18F-FDG PET scans. The median values of MRglc at S2, S3 and S4 determined using a simplified kinetic method (SKM) were, respectively, 0.05, 0.06 and 0.07 μmol/min/g for tumors with local control and 0.12, 0.16 and 0.19 μmol/min/g for tumors with local failure, and the maximum standard uptake values (SUVmax) were 1.16, 1.33 and 1.45 for tumors with local control and 2.74, 2.74 and 4.07 for tumors with local failure (p < 0.0001). MRglc-MMR was realized at S2 (MRglc-S2) and the values corresponding to TCP 95 %, 90 % and 50 % were 0.036, 0.050 and 0.134 μmol/min/g using the SKM and 0.70, 0.91 and 1.95 using SUVmax, respectively. Probability cut-off values were generated for a given level of MRglc-S2 based on its predicted TCP, sensitivity and specificity, and MRglc ≤0.071 μmol/min/g and SUVmax ≤1.45 were determined as the optimum cut-off values for predicted TCP 80 %, sensitivity 100 % and specificity 63 %. Conclusion: The cut-off values (MRglc ≤0.071 μmol/min/g using the SKM and SUVmax ≤1.45) need to be tested for their utility in identifying patients with a high risk of residual cancer after standard dose radiotherapy or chemoradiotherapy and in guiding a timely supplementary dose of radiation or other means of salvage therapy. Electronic supplementary material The online version of this article (doi:10.1007/s00259-013-2348-4) contains supplementary material, which is available to authorized users
Recommended from our members
Direct Evidence that Bevacizumab, an Anti-VEGF Antibody, Up-regulates SDF1 , CXCR4, CXCL6, and Neuropilin 1 in Tumors from Patients with Rectal Cancer
Clinical studies converge on the observation that circulating cytokines are elevated in most cancer patients by anti-vascular endothelial growth factor (VEGF) therapy. However, the source of these molecules and their relevance in tumor escape remain unknown. We examined the gene expression profiles of cancer cells and tumor-associated macrophages in tumor biopsies before and 12 days after monotherapy with the anti-VEGF antibody bevacizumab in patients with rectal carcinoma. Bevacizumab up-regulated stromal cell-derived factor 1alpha (SDF1alpha), its receptor CXCR4, and CXCL6, and down-regulated PlGF, Ang1, and Ang2 in cancer cells. In addition, bevacizumab decreased Ang1 and induced neuropilin 1 (NRP1) expression in tumor-associated macrophages. Higher SDF1alpha plasma levels during bevacizumab treatment significantly associated with distant metastasis at three years. These data show that VEGF blockade up-regulates inflammatory pathways and NRP1, which should be evaluated as potential targets for improving anti-VEGF therapy
Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer
BACKGROUND: To determine the maximum tolerated dose (MTD) and safety, and explore efficacy and biomarkers of vandetanib with cetuximab and irinotecan in second-line metastatic colorectal cancer. METHODS: Vandetanib (an orally bioavailable VEGFR-2 and EGFR tyrosine kinases inhibitor) was combined at 100 mg, 200 mg, or 300 mg daily with standard dosed cetuximab and irinotecan (3+3 dose-escalation design). Ten patients were treated at the MTD and plasma angiogenesis biomarkers (VEGF, PlGF, bFGF, sVEGFR1, sVEGFR2, IL-1β, IL-6, IL-8, TNF-α, SDF1α) were measured before and after treatment. RESULTS: Twenty-seven patients were enrolled at 4 dose levels and the MTD. Two dose-limiting toxicities (grade 3 QTc prolongation and diarrhea) were detected at 300 mg of vandetanib with cetuximab and irinotecan resulting in 200 mg being the MTD. Seven percent of patients had a partial response, 59% stable disease and 34% progressed. Median progression-free survival was 3.6 months (95% CI, 3.2-5.6) and median overall survival was 10.5 months (95% CI, 5.1-20.7). Toxicities were fairly manageable with grade 3 or 4 diarrhea being most prominent (30%). Vandetanib and cetuximab treatment induced a sustained increase in plasma PlGF and a transient decrease in plasma sVEGFR1, but no changes in plasma VEGF and sVEGFR2. CONCLUSIONS: Vandetanib can be safely combined with cetuximab and irinotecan for metastatic colorectal cancer. Exploratory biomarker analyses suggest differential effects on certain plasma biomarkers for VEGFR inhibition when combined with EGFR blockade and a potential correlation between baseline sVEGFR1 and response. However, while the primary endpoint was safety, the observed efficacy raises concern for moving forward with this combination. TRIAL REGISTRATION: Clinicaltrials.gov NCT00436072
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients
Preoperative bevacizumab and chemotherapy may benefit a subset of breast cancer (BC) patients. To explore potential mechanisms of this benefit, we conducted a phase II study of neoadjuvant bevacizumab (single dose) followed by combined bevacizumab and adriamycin/cyclophosphamide/paclitaxel chemotherapy in HER2-negative BC. The regimen was well-tolerated and showed a higher rate of pathologic complete response (pCR) in triple-negative (TN)BC (11/21 patients or 52%, [95% confidence interval (CI): 30,74]) than in hormone receptor-positive (HR)BC [5/78 patients or 6% (95%CI: 2,14)]. Within the HRBCs, basal-like subtype was significantly associated with pCR (P = 0.007; Fisher exact test). We assessed interstitial fluid pressure (IFP) and tissue biopsies before and after bevacizumab monotherapy and circulating plasma biomarkers at baseline and before and after combination therapy. Bevacizumab alone lowered IFP, but to a smaller extent than previously observed in other tumor types. Pathologic response to therapy correlated with sVEGFR1 postbevacizumab alone in TNBC (Spearman correlation 0.610, P = 0.0033) and pretreatment microvascular density (MVD) in all patients (Spearman correlation 0.465, P = 0.0005). Moreover, increased pericyte-covered MVD, a marker of extent of vascular normalization, after bevacizumab monotherapy was associated with improved pathologic response to treatment, especially in patients with a high pretreatment MVD. These data suggest that bevacizumab prunes vessels while normalizing those remaining, and thus is beneficial only when sufficient numbers of vessels are initially present. This study implicates pretreatment MVD as a potential predictive biomarker of response to bevacizumab in BC and suggests that new therapies are needed to normalize vessels without pruning
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients
Effects of Sorafenib on Intra-Tumoral Interstitial Fluid Pressure and Circulating Biomarkers in Patients with Refractory Sarcomas (NCI Protocol 6948)
Purpose: Jain Sorafenib is a multi-targeted tyrosine kinase inhibitor with therapeutic efficacy in several malignancies. Sorafenib may exert its anti-neoplastic effect in part by altering vascular permeability and reducing intra-tumoral interstitial hypertension. As correlative science with a phase II study in patients with advanced soft-tissue sarcomas (STS), we evaluated the impact of this agent on intra-tumor interstitial fluid pressure (IFP), serum circulating biomarkers, and vascular density. Patients and Methods: Patients with advanced STS with measurable disease and at least one superficial lesion amenable to biopsy received sorafenib 400 mg twice daily. Intratumoral IFP and plasma and circulating cell biomarkers were measured before and after 1–2 months of sorafenib administration. Results were analyzed in the context of the primary clinical endpoint of time-to-progression (TTP). Results: In 15 patients accrued, the median TTP was 45 days (range 14–228). Intra-tumoral IFP measurements obtained in 6 patients at baseline showed a direct correlation with tumor size. Two patients with stable disease at two months had post-sorafenib IFP evaluations and demonstrated a decline in IFP and vascular density. Sorafenib significantly increased plasma VEGF, PlGF, and SDF1 and decreased sVEGFR-2 levels. Increased plasma SDF1 and decreased sVEGFR-2 levels on day 28 correlated with disease progression. Conclusions: Pretreatment intra-tumoral IFP correlated with tumor size and decreased in two evaluable patients with SD on sorafenib. Sorafenib also induced changes in circulating biomarkers consistent with expected VEGF pathway blockade, despite the lack of more striking clinical activity in this small series
Evaluation of the work of modified swirl sedimentation tank for purification of rainwater stream contaminated by light fraction
Omówiono zmodyfikowaną konstrukcję osadnika wirowego użytego do rozdzielania frakcji lekkich z wody. Klasyczny osadnik wirowy wyposażono dodatkowo w cylinder wewnętrzny, który oddzielał strefę rozdzielania oleju od strefy wylotowej osadnika. Celem modyfikacji konstrukcji było przede wszystkim umożliwienie zatrzymywania frakcji lekkiej w osadniku w porównaniu do standardowego osadnika wirowego, którego zadaniem jest odseparowanie tylko frakcji ciężkiej. Ocenie poddano spiętrzenie cieczy oraz sprawność aparatu w zależności od natężenia przepływu zanieczyszczonej cieczy.In the paper a modified construction of swirl sedimentation tank for separation of light fraction from water is proposed. The classical swirl sedimentation tank was equipped with the additional inner cylinder splitting the separation and outlet oil zones. The aim of construction modification was to enable the retention of light fraction in the tank in comparison with the classical swirl sedimentation tank which function is to separate only heavy fraction. The liquid damming and tank efficiency as a dependence on the contaminated liquid flow rate were evaluated
Study on efficiency of rainwater stream purification in a swirl sedimentation tank
Przedstawiono różne konstrukcje osadników wirowych, badania doświadczalne spiętrzeń cieczy oraz sprawności oczyszczania strumienia zanieczyszczonej cieczy. Głównym celem modyfikacji konstrukcji było zwiększenie sprawności aparatów w odniesieniu do standardowego osadnika wirowego. Projektowanie, konstruowanie oraz badania osadników wirowych mogą prowadzić do poprawy efektywności usuwania zanieczyszczeń z cieczy oraz ewentualnego zmniejszenia wielkości urządzeń.The paper presents different structures of swirl sedimentation tanks, experimental studies of water damming-up and efficiency of polluted liquid stream purification. The main aim of modification was the increase of apparatus efficiency in relation to the standard swirl sedimentation tank. The design, structure and testing of swirl sedimentation tank may lead to the improvement of removal efficiency of contaminants in liquid and possibly the reduction of apparatus size
Analysis of selected parameters’ impact on air purification in a chamber separator based on swirl motion phenomenon
Przedstawiono wyniki badań doświadczalnych i analizę sprawności procesu odpylania dla cylindrycznego odpylacza komorowego wykorzystującego ruch wirowy. Wykazano, że skuteczność odpylania wzrasta ze wzrostem średnicy cząstki ciała stałego oraz zmniejszeniem natężenia przepływu gazu. Dużą sprawność odpylania uzyskano dzięki wykorzystaniu ruchu wirowego. Cylindryczny kształt odpylacza pozwala na oszczędność materiałów konstrukcyjnych, a tym samym na zmniejszenie kosztów.The paper presents the experimental results and efficiency analysis of dust removal in a cylindrical chamber separator with swirl motion effect. It was shown that the separation efficiency increased with the increasing of particle diameter and decreasing of gas flow rate. The high separation efficiency is achieved by using swirl motion effect. A cylindrical shape of the separator gives the possibility of materials saving and thus costs reduction
- …